Department of Radiation Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.
Department of Radiology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.
Radiat Oncol. 2018 Dec 3;13(1):238. doi: 10.1186/s13014-018-1189-5.
Volumetric shrinkage of normal tissues such as salivary glands, kidneys, hippocampus are observed after radiotherapy. We aimed to assess the alterations in pancreatic volume of patients who received abdominal radiotherapy and define pancreas as an organ at risk for radiation treatment planning.
MATERIAL-METHODS: Forty-nine patients operated for gastric adenocarcinoma who received adjuvant abdominal radiotherapy were in the study group, 27 patients with early stage disease who did not need adjuvant treatment after surgery comprised the control group. An experienced radiologist contoured the pancreas of all the patients from computed tomographies imported to the planning system obtained either for radiation planning purpose or for follow-up after surgery. The same procedure was repeated one year later for both groups. Measured volume of the pancreas was expressed in cm.
Mean pancreatic volumes were similar in both groups at the onset of the study, 51,34 ± 20,33 cm, and 50,12 ± 23,75 cm in the irradiated and the control groups respectively (p = 0,63). One year later, mean pancreatic volumes were significantly decreased in each group; 22,48 ± 10,53 cm, 44,18 ± 23,08 cm respectively, p < 0,001. However, the decrease in pancreatic volume was significantly more pronounced in the irradiated group in comparison to the control group, p < 0,001.
Volumetric decrease in normal tissues after radiotherapy is responsible for loss of organ function and radiation related late side effects. Although pancreas is a radiation sensitive organ losing its volume and function after radiation exposure, it is not yet considered as an organ at risk for radiation treatment planning. Pancreas should be contoured as an organ at risk, dose-volume histogram for the organ should be created, and safe organ doses should be determined. This is the first study declaring pancreas as an organ at risk for radiation toxicity and the necessity of defining dose constraints for the organ.
在接受放射治疗后,正常组织(如唾液腺、肾脏、海马体)会出现体积缩小。我们旨在评估接受腹部放射治疗的患者胰腺体积的变化,并将胰腺定义为放射治疗计划中的危险器官。
研究组纳入 49 例因胃腺癌接受辅助腹部放疗的患者,对照组纳入 27 例早期疾病患者,手术后无需辅助治疗。一位经验丰富的放射科医生从为放射治疗计划或手术后随访而导入计划系统的计算机断层扫描中勾画出所有患者的胰腺。两组均在研究开始时、一年后重复该程序。胰腺的测量体积以立方厘米表示。
在研究开始时,两组的平均胰腺体积相似,分别为 51.34±20.33cm 和 50.12±23.75cm(p=0.63)。一年后,两组的平均胰腺体积均显著下降;分别为 22.48±10.53cm 和 44.18±23.08cm(p<0.001)。然而,与对照组相比,照射组胰腺体积的减少更为明显,p<0.001。
放射治疗后正常组织的体积减少是导致器官功能丧失和放射相关晚期副作用的原因。尽管胰腺是一种对辐射敏感的器官,在受到辐射后会失去其体积和功能,但它尚未被认为是放射治疗计划中的危险器官。应将胰腺勾画为危险器官,为该器官创建剂量-体积直方图,并确定安全的器官剂量。这是第一项宣布胰腺为放射毒性危险器官并确定器官剂量限制必要性的研究。